Plenary Keynote Presentation & Keynote Sessions

Tuesday, February 16

PLENARY KEYNOTE SESSION

POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS

10:55 am FDA Update on COVID-19 Molecular Diagnostic Testing
Timothy StenzelTimothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA


11:15 Sponsored Presentation (Opportunity Available)

11:20 RADx Tech: A New Paradigm for MedTech Development
Steven SchachterSteven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT
On April 24, 2020, Congress appropriated $1.5 billion for SARS-CoV-2 testing to the NIH. Within 5 days after the legislation was signed into law, the NIH launched RADx Tech to support the development, production scale-up, and deployment of accurate, rapid tests across the country. One of the goals of the RADx Tech initiative was to expand capacity so that by December 2020, approximately 2% of the U.S. population (6 million persons) can be tested per day, with more tests ready for rapid deployment in proportion to national demand. During its first six months, the RADx Tech program evaluated over 700 applications and moved 22 projects into large-scale manufacturing. There are numerous unprecedented aspects of RADx Tech that make it a validated model for medtech development, as will be detailed in this presentation.

11:40 Sponsored Presentation (Opportunity Available)

11:45 From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared Us to Respond to This Pandemic
Robert A. JohnsonRobert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services



12:05 pm Sponsored Presentation
Speaker to be Announced

12:10 Global Public Health Consortium: A Path for Global Biosecurity through Equity and Transparency
W. Ian LipkinW. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University
COVID-19 has exposed our vulnerability to pandemic risk and the urgency of addressing the challenges of climate change, food security, and the viral dissemination of misinformation. New molecular diagnostic platforms, investments in wildlife, domestic animal, and human microbial surveillance, and the advent of social media tools that mine the world wide web for clues to outbreaks of infectious disease are all proving invaluable in early recognition of threats to public health. However, inequities in the distribution of resources required for diagnostics and discovery, and lack of trust and transparency remain threats to biosecurity. To address these challenges, we are establishing a global public health consortium comprising of ministries of health and academic institutions. This collaborative global program will focus on creating an infectious disease epidemiology network and has three main objectives: (1) develop a model realizing and extending the goals of the International Health Regulations established by the WHO in 2005 by providing inexpensive, rapid tools for diagnosis discovery, and surveillance of infectious diseases, (2) identify and prioritize infectious agents based on pandemic risk, and (3) share data and build the infrastructure needed to produce, validate and implement drugs and vaccines to reduce morbidity and mortality.

Wednesday, February 17

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 am Women in Science

Panelists:

Hanneke SchuitemakerHanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center


Carolyn ComptonCarolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance


Malileh PoorfarhaniMalileh Poorfarhani, Director, Digital Health and R&D, Bayer


PLENARY KEYNOTE SESSION

BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS

1:20 pm Exploring New Therapies for COVID-19: Focus on AstraZeneca’s Long-Acting Monoclonal Antibody Combination
Mark T. EsserMark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca
This talk will provide an overview of convalescent plasma and monoclonal antibodies currently in development for treating COVID-19 with a focus on the discovery and development of AstraZeneca's long-acting antibody (LAAB) combination (AZD7442) currently being evaluated for both the prevention and treatment of COVID-19.

1:40 Sponsored Presentation (Opportunity Available)

1:45 Janssen’s Efforts in the Development of a COVID-19 Vaccine
Hanneke SchuitemakerHanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center
In response to the COVID-19 pandemic, Janssen Pharmaceuticals of Johnson and Johnson is developing an Adeno 26-vector based COVID-19 vaccine. Results from preclinical- and clinical studies with Janssen’s lead candidate Ad26.COV2.S, that encodes a stabilized SARS-CoV-2 Spike (S) protein, will be presented. This vaccine candidate is now being tested as the only single dose regimen in a phase 3 efficacy study.

2:05 Sponsored Presentation (Opportunity Available)

2:10 Developing a COVID Vaccine in Ten Months
Sanjay GurunathanSanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur


Thursday, February 18

PLENARY KEYNOTE SESSION

PRECISION MEDICINE AT BIG PHARMA

11:40 am Turning Science into Medicine: The Power of Collaboration
Mene N. PangalosMene N. Pangalos, PhD, Executive Vice President Biopharmaceuticals R&D, AstraZeneca
The rate of change across healthcare is more rapid than ever before and although 2020 has been challenging, it has forced us to think progressively about how we enable and execute the discovery and development of the next wave of life-changing medicines to patients. Because of the investment we have been making in transformative technologies, digital health solutions, and data science and AI in clinical trial innovation, we have enabled existing trials to continue safely and at speed through remote data collection from home. Scientists in our labs have rapidly applied their expertise in diagnostics, high-throughput screening and infectious diseases, developing new treatments and preventative approaches to combat the virus. This has shown how we can adapt quickly, work seamlessly across partners and accelerate the introduction of new ways of working to fast-forward the pace of science. Creating R&D organizations that are integrated and collaborative means we are fit for the future – whatever that may hold – and it is this strength which allows us to continue transforming science to create the greatest and swiftest impact on the diseases we aim to treat, prevent and in the future even cure.

12:00 pm Sponsored Presentation (Opportunity Available)

12:05 Talk Title to be Announced
Hakan SakulHakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer


12:25 Sponsored Presentation (Opportunity Available)

12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator:
Cecilia Schott, PharmDCecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis


Panelists:

Hakan SakulHakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer


Maria C. M. OrrMaria C. M. Orr, PhD, FRSB, Head of Precision Medicine, Biopharmaceuticals, AstraZeneca


Additional panelists to be announced



Premier Sponsors

10x-genomics-logo

Burning-Rock-Dx

NeoGenomics

PrecisionForMedicine_NoTagline



RareCyte

Seegene